BeOne Medicines (NASDAQ:ONC) CEO Sells $19,503,984.99 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 61,397 shares of BeOne Medicines stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99. Following the completion of the sale, the chief executive officer directly owned 9,180 shares in the company, valued at $2,916,210.60. This represents a 86.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The shares were sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total transaction of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The stock was sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Down 1.6%

Shares of NASDAQ ONC opened at $322.08 on Friday. The stock has a market cap of $35.34 billion, a PE ratio of 72.05 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $253.95 and a 12-month high of $385.22. The company has a 50-day moving average of $293.39 and a 200 day moving average of $309.31.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current fiscal year.

Analysts Set New Price Targets

ONC has been the subject of several analyst reports. Wells Fargo & Company started coverage on BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price for the company. Royal Bank Of Canada boosted their price target on shares of BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Barclays dropped their price objective on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating for the company in a report on Tuesday, July 14th. Nomura upgraded shares of BeOne Medicines to a “strong-buy” rating in a research report on Monday. Finally, Guggenheim boosted their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $394.00.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds have recently modified their holdings of the business. EFG International AG purchased a new stake in BeOne Medicines in the 4th quarter valued at about $25,000. Leonteq Securities AG purchased a new position in BeOne Medicines during the fourth quarter worth about $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines during the second quarter worth about $35,000. CWM LLC increased its position in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines during the fourth quarter valued at about $61,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.